Phase II Clinical Study of Imatinib Mesylate in Patients With Malignant Gastrointestinal Stromal Tumors (Extension Study)

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00237172

Enrollment

Registered

2005-10-12

Start date

2002-09-30

Completion date

Unknown

Last updated

2012-05-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastrointestinal Stromal Tumors

Keywords

GIST, Imatinib, STI571, Gastrointestinal Stromal Tumors

Brief summary

This is a extension study of CSTI571B1201 study

Interventions

DRUGImatinib Mesylate

once daily

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

20 Years to 74 Years

Healthy volunteers

Inclusion criteria

\- Patients who completed the CSTI571B1201 study

Exclusion criteria

\- Other protocol-defined inclusion /

Design outcomes

Primary

Measure	Time frame
To study the antineoplastic effect of the investigational drug.	—

Secondary

Measure	Time frame
To study the safety and pharmacokinetics of the investigational drug.	—

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026